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Abstract
Background: Dysregulated immune responses may contribute to the clinical complications that occur in some patients with
dengue.
Findings: In Vietnamese pediatric dengue cases randomized to early prednisolone therapy, 81 gene-transcripts (0.2% of the
47,231 evaluated) were differentially abundant in whole-blood between high-dose (2 mg/kg) prednisolone and placebo-
treated patients two days after commencing therapy. Prominent among the 81 transcripts were those associated with T and
NK cell cytolytic functions. Additionally, prednisolone therapy was not associated with changes in plasma cytokine levels.
Conclusion: The inability of prednisolone treatment to markedly attenuate the host immune response is instructive for
planning future therapeutic strategies for dengue.
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Introduction
Dengue is an acute, mosquito-borne illness caused by any of the
four types of dengue virus (DENV1-4). There are an estimated 390
million symptomatic and asymptomatic infections per year [1].
The clinical evolution is variable, ranging from non-specific febrile
illness to severe and sometimes fatal disease. One of the
commonest complications observed is a transient vasculopathy,
manifesting as increased vascular permeability with altered
haemostasis, typically 3–6 days after fever onset. Dysregulated
host immune responses, particularly those associated with second-
ary infections, are widely held to contribute mechanistically to the
vasculopathy that characterizes severe dengue [2]. No specific
therapies or licensed vaccines are currently available and
management relies on assiduous supportive care.
Synthetic glucocorticoids are frequently employed as adjunctive
therapy in disease states where the host immune response is
thought to be a significant contributor to disease pathogenesis. We
recently performed a randomized, controlled trial of early oral
prednisolone therapy in 225 confirmed pediatric dengue cases [3].
Although the trial was primarily designed to assess safety we were
unable to detect any reduction in the severity of plasma leakage or
other recognised complications of dengue. We report here on
immunological correlates of prednisolone therapy in this trial with
a view to understanding the lack of clinical benefit imparted by
prednisolone and to guide future intervention strategies for
dengue.
Materials and Methods
Patient population and clinical methods
A randomized, placebo-controlled double-blind trial assessing
the safety of early oral corticosteroid therapy in dengue patients
was conducted at the Hospital for Tropical Diseases, Ho Chi Minh
City, Vietnam between August 2009 and January 2011 as
approval from the Ethical Committee of the Ministry of Health
of Vietnam (2407/QD–-BYT) and the Oxford Tropical Research
Ethics Committee (OxTREC 33-08) and has been reported
elsewhere [3]. The trial registration number is ISRCTN39575233.
Briefly, patients aged from 5–20 years with fever for less than
72 hrs and a positive dengue NS1 rapid test were randomly
allocated to oral treatment with high-dose prednisolone (2 mg/kg),
low-dose prednisolone (0.5 mg/kg) or identical placebo for 3 days
provided the patient or their parent/guardian gave written
informed consent and children 12–17 years gave assent; all
patients recovered fully and we found no association between
treatment allocation and any of the predefined clinical, haema-
tological or virological endpoints. The research blood specimens
that form the basis of the work described here were collected as
part of the trial protocol at pre-specified time-points: enrolment
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(pre-treatment); 2 days post initiation of treatment; and at follow-
up in late convalescence (median 29 (IQR 27, 30) days after
enrolment). To facilitate interpretation of the findings with respect
to defervescence, the first day that the temperature fell to 37.5uC
or less and remained below this level for 48 hours or until
discharge was taken as the day of deferescence; fever day 0 was
defined as the calendar day of defervescence, with days before this
point numbered consecutively as fever days 21, 2 2, 2 3
respectively.
Cytokines
Eleven cytokines (IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70,
IL-13, IFNc, TNFa and IP10) were quantified using a multi-
plex biometric immunoassay following the instructions of the
manufacturer (Bio-Plex Precision Pro Assays, Human cytokine 10-
Plex, Bio-Rad Inc., USA). The limits of detection were as follows:
0.23 (IL-1b), 0.84 (IL-2), 0.14 (IL-4), 1.5 (IL-5), 1.23 (IL-6), 0.96 (IL-
10), 0.2 (IL-12p70), 1.19 (IL-13), 0.34 (IFN-c), 0.14 (TNF-a) and 10
(IP10), all pg/ml.
Gene expression microarray and PCR validation
The gene expression microarray assay, and the procedures for
normalization and analysis of the microarray data were conducted
as described elsewhere [4]. Samples from the first 123 consecutive
patients enrolled in the study were used as the ‘‘discovery’’ cohort.
A fluidigm system (Fluidigm Corp., USA) was used for realtime
PCR (RT-PCR) validation of those differentially abundant
transcripts identified in the gene expression microarray, using
samples from the whole patient cohort and following the
manufacturer’s instructions. The delta Ct value for each gene
was calculated by subtracting the Ct value of the gene of interest
from the Ct value of 18S, the house-keeping gene.
Data analysis
All group comparisons of microarray data were based
on ANOVA with correction for multiple testing with the
Benjamini-Hochberg method, as implemented in the GeneSpring
Software (Silicon Genetics). A fold change of 1.5 was defined as the
cut-off for screening significant entities. We used multivariable
linear regression modeling for all comparisons of PCR results,
expressed as delta Ct values, between the treatment arms. For the
overall comparison across treatment arms, a linear trend test was
used. In view of the likely evolution of gene expression during the
illness episode, and the known associations of many of the genes of
interest to immune parameters, we adjusted for day of illness and
the absolute neutrophil and lymphocyte counts. Additionally we
adjusted for the pre-treatment value when examining within-
patient changes in delta Ct over time. P values for testing of
multiple PCR results were corrected using the Benjamini-
Hochberg method. The relative expression ratios of the genes
between the treatment arms were estimated using the delta delta
Ct formula: R= 22DDCt with corresponding 95% confidence
intervals based on the bootstrap. Genes with significantly different
relative expression ratios between treatment arms (i.e. adjusted
p,0.05 and 95%CI not including 1) were considered up or down
regulated as appropriate.
Multivariable linear regression was used for all comparisons of
log-transformed values of cytokine concentrations adjusting for
day of illness and pre-treatment values and linear trend tests
performed as described above. All the analyses were corrected for
multiple tests using the Benjamini-Hochberg method. All analyses
other than those pertaining to the microarray data were performed
using R, version R2.13.2 (R Foundation for Statistical Computing,
Vienna, Austria).
Microarray data accession number. The GEO accession
number for microarray data is GSE40165
Results
Differentially abundant gene expression linked to
high-dose prednisolone therapy
Baseline characteristics for the first 123 dengue patients
consecutively enrolled in the trial who formed the discovery cohort
are described in Table 1 together with similar information for the
223 patients used for the PCR validation; clinical and laboratory
features were similar across the three intervention arms. At
enrolment, none of the 47,231 transcripts evaluated in the
microarray were differentially abundant between groups of patients
allocated to different treatment arms. Similarly, there were no
transcripts differentially abundant between treatment groups in late
convalescence, or between placebo and low-dose prednisolone
patients 2 days after commencing treatment. By contrast, 81
differentially abundant transcripts (25 that were more abundant and
56 less abundant), representing 67 genes, were detected when
comparing whole-blood gene expression profiles between the high-
dose prednisolone and placebo groups 2 days after commencing
treatment. RT-PCR validation measurements were targeted to a
subgroup of 31 (46%) of the 67 genes on the basis of their having
plausible roles in immune function. RT-PCR validation was
performed with 600 whole blood RNA samples collected at baseline
(N=208), 2 days after starting treatment (N=200), and in late-
convalescence (N=192) from 223 (99%) of the 225 patients in the
trial. With the exception of one target (CLIC3), RT-PCR
measurements were entirely concordant with the microarray
findings (Figure 1). Annotation of RT-PCR validated gene elements
enabled functional grouping according to their recognized roles in
NK and T cell cytolytic function, T cell activation and innate
immune responses (Figure 1). These analyses were extended by
investigating a prednisolone dose-response (placebo, low-dose, high
dose) relationship. After adjustment for the a priori defined variables
Author Summary
Dengue is an acute, mosquito-borne febrile illness and
around 390 million cases occur annually in more than 100
countries. A host pro-inflammatory immune response is
widely believed to contribute to the clinical complications
that occur in some patients with dengue. Synthetic
glucocorticoids, which are immunomodulatory agents
commonly used in medicine, have been suggested as a
therapy for dengue. We recently performed a randomized,
controlled trial of early oral glucocorticoid therapy in 225
dengue cases in Vietnam, comparing a three day regimen
of high (2 mg/kg) or low (0.5 mg/kg) dose prednisolone
with placebo. Here, we report on immunological changes
occurring during prednisolone therapy with a view to
understanding the lack of clinical benefit by glucocorticoid
therapy and to guide future intervention strategies for
dengue. In whole-blood gene expression arrays we found
81 transcripts from 64 genes differentially abundant
between high-dose prednisolone and placebo treated
patients. Prominent were the genes associated with T and
NK cell cytolytic functions. These results are a reminder
that the mechanisms causally behind some of the
complications of dengue (e.g. altered capillary permeabil-
ity) are very poorly understood and represent a major
knowledge gap in our understanding of disease patho-
genesis that also undermines attempts to improve clinical
management.
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(day of illness, absolute neutrophil and lymphocyte counts, baseline
transcript abundance), a highly significant prednisolone dose-
related effect on gene transcript abundance was observed for all
31 transcripts (Table S1). Collectively, these results define a discrete
gene transcript profile that is associated with high-dose prednisolone
therapy in dengue patients.
Plasma cytokines and prednisolone therapy
Concentrations of 11 cytokines and chemokines were measured
in 636 serial plasma samples from 222 patients at the three time-
points. Although cytokine/chemokine concentrations were within
the detectable range in 98% of samples tested, their levels were not
significantly elevated during the acute phase of illness compared to
follow-up, and there were no significant differences between
treatment groups 2 days after starting therapy (Table 2).
Discussion
The current study was linked to a randomized controlled trial of
early prednisolone therapy for dengue that demonstrated the safety of
prednisolone but did not provide evidence of improved clinical or
laboratory outcomes for patients [3]. Here we provide insights into
these trial findings by identifying a surprisingly small prednisolone-
associated footprint (just 81 transcripts differentially abundant from
47,231 evaluated) on the whole-blood gene expression profile that
manifests during DENV infection. Furthermore, acute-phase plasma
cytokine concentrations were not measurably attenuated by prednis-
olone treatment. The limited immunomodulation achieved by
prednisolone is consistent with it having negligible measurable
benefits in the clinical trial in which this current study was nested.
Dysregulated immune responses are widely believed to contrib-
ute to the pathogenesis of severe dengue [2], and hence
corticosteroid therapy has been trialed in several small studies of
patients with shock due to vascular leakage [5,6]. No benefit was
demonstrated in those studies, but treatment was initiated when
shock was already established, when it is probably too late to
modulate the host immune response. In our recent intervention
study prednisolone was commenced during the early febrile phase,
but we were still unable to demonstrate any amelioration in the
severity of plasma leakage. Against a backdrop where the
immunomodulatory actions of corticosteroids are well established
[7,8], it is surprising that we did not observe stronger signals of
immune-modulation. The absence of a measurable impact of
prednisolone on plasma cytokine concentrations two days after
enrolment reflects the absence of any significant elevation of the 11
cytokines/chemokines in the acute phase compared to convales-
cence. This is at odds with a body of literature indicating elevated
plasma/serum cytokine concentrations are a prominent feature in
the host response [9]. However a limitation of this current study,
unlike previous work [10,11], was that we did not measure
cytokine/chemokine concentrations in serial daily plasma speci-
mens and therefore we may have missed transient changes in
particular markers.
Changes in the whole-blood host gene expression profile occurred
in patients that had received 2 mg/kg prednisolone (but not 0.5 mg/
kg) compared to placebo-treated patients. This is to our knowledge
the first ex vivo and ‘‘global’ investigation of the effect of prednisolone
on the host immune response during an infectious disease. A striking
finding, that was independent of the blood lymphocyte count, was the
prednisolone-associated under-abundance of transcripts representing
Table 1. Enrolment characteristics of patients sampled for the microarray and RT-PCR investigations.
Microarray population RT-PCR population
(N=123(a)) (N=223(b))
Placebo Low-dose High-dose Placebo Low-dose High-dose
(N=40) (N=42) (N=41) (N=75) (N=74) (N=74)
Sex, female 11 (28) 11 (26) 16 (39) 19 (25) 21 (28) 24 (32)
Age, years 13 (11–14) 11 (10–14) 12 (10–13) 13 (12–15) 12 (11–14) 12 (10–14)
Day of illness
Day 1 0 (-) 0 (-) 1 (2) 0 (-) 1 (1) 1 (1)
Day 2 17 (42) 14 (33) 16 (39) 28 (37) 23 (31) 29 (39)
Day 3 23 (58) 28 (67) 24 (59) 47 (63) 50 (68) 44 (59)
Fever day* 25 (26, 24) 24 (26, 24) 25 (26, 24) 25 (26, 24) 24 (26, 24) 24 (26, 24)
Serotype
DENV-1 27 (68) 27 (64) 29 (71) 41 (55) 46 (62) 49 (66)
DENV-2 11 (28) 8 (19) 3 (7) 29 (39) 17 (23) 11 (15)
DENV-3 2 (5) 5 (12) 6 (15) 4 (5) 9 (12) 10 (14)
DENV-4 0 (-) 2 (5) 3 (7) 1 (1) 2 (3) 4 (5)
Total WBC (103/mL) 3.1 (2.5–4.3) 4.0 (3.0–5.9) 4.2 (2.7–5.8) 3.8 (2.7–5.0) 3.7(c) (3.0–5.4) 4.2(c) (3.0–5.2)
Neutrophils (103/mL) 2.2 (1.3–3.1) 2.7 (1.8–4.1) 2.8 (2.0–3.6) 2.6 (1.7–3.5) 2.5(c) (1.7–3.9) 2.9(c) (2.0–3.8)
Lymphocytes (103/mL) 0.7 (0.5–0.9) 0.7 (0.5–1.0) 0.7 (0.5–1.0) 0.7 (0.6–0.9) 0.7(c) (0.5–0.9) 0.7(c) (0.5–1.0)
Continuous variables are summarized as median (IQR), categorical variables are summarized as number and frequency (%).
(a)358 whole-blood RNA samples from the first 123 consecutively enrolled patients were included in the microarray experiment. 11 follow-up samples were missing.
(b)600 samples from 223 patients (including the123 patients that were sampled for the microarray) were included in the RT-PCR validation study. (15 pre-treatment, 23
post-treatment and 31 follow-up samples were either missing or of poor quality and were therefore not included).
(c)There was one missing value.
(*)Fever day (median (IQR) refers to the day of enrolment relative to the day of defervescence, defined as fever day 0.
doi:10.1371/journal.pntd.0002592.t001
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granzyme B (GZMB), granzyme H (GZMH), granulysin (GNLY),
perforin (PRF1), Ksp37 (FGFBP2) and cathepsinW (CTSW), each of
which is associated with the secretory and cytolytic activities of T and
NK cells. Taken together, the diminished abundance of transcripts
encoding T and NK effector proteins might suggest impaired anti-
viral cytolytic responses during high-dose prednisolone therapy.
Figure 1. Fold difference in transcript abundance between high-dose prednisolone and placebo treated patients 2 days post
initiation of treatment. Shown is the ratio in abundance of transcripts measured by microarray and by RT-PCR for the 67 genes that distinguished
high-dose prednisolone treated patients from placebo treated patients. Where results from multiple probes in the microarray were available for 1
gene, we used the mean result. Genes have been grouped and annotated according to their recognized biological functions. Median (IQR) times from
a) the start of treatment and b) the most recent dose, to the time of the microarray sample were similar; 43 (42–43) hours and 23 (22–24) hours for the
high-dose prednisolone recipients, and 43 (42–44) hours and 22 (22–23) hours for the placebo recipients.
doi:10.1371/journal.pntd.0002592.g001
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However prolonged viremia levels were not observed in predniso-
lone-treated patients [3]. It is plausible that the lower transcript
abundance of these elements in whole blood is not biologically
significant in terms of resolving infection and that other components
of the immune response, such as antibodies or complement, are more
important and/or compensatory.
Transcripts from neutrophils, independent of the absolute
neutrophil count, were more abundant in high-dose prednisolone
treated patients. This included three neutrophil markers (IL1R2,
S100A12 and ORM1), all known to be corticosteroid induced
[12–14]; interestingly these markers were also independently
identified as being elevated at a similar timepoint in relation to
defervescence (fever day 22 to 23) in a previous study of 35
Vietnamese children who subsequently developed DSS ([4]).
Further studies will be required to understand if prednisolone
exacerbates the functional neutrophil response in addition to its
well-described demargination effects [15] [16].
There are limitations to our study. We did not measure
complement activation yet there is good evidence that complement
is consumed and split products generated in the course of dengue
and that this might be important to pathogenesis [17]. Our
sampling schedule may have missed transient but important
differences in cellular gene expression signals between patients in
different treatment arms. Prednisolone may also have actions in
tissues that are not revealed in whole blood. Nevertheless the results
of this study, coupled with the findings from the clinical trial [3],
suggest that early prednisolone therapy has little impact on the host
immune response or the clinical evolution of dengue. One possible
explanation is that early prednisolone therapy is ‘‘too little, too late’’
to attenuate the infection-driven processes that lead to the altered
capillary permeability, thrombocytopenia, and haemostatic de-
rangements. We can only speculate that even earlier treatment, or
higher dose therapy, might have led to a greater prednisolone
impact on the immune response and clinical/laboratory phenotype.
Notwithstanding these limitations, the results described here
underscore the challenge of modulating an immune response that
has been driven by days of DENV replication in host tissues. More
fundamentally, these results are a reminder that although immune-
driven pathophysiological changes are good candidates to explain
capillary permeability, the precise causal mechanisms remain
poorly understood. This represents a major knowledge gap in our
understanding of disease pathogenesis that also undermines
development of specific therapies.
Supporting Information
Table S1 Genes with significantly different transcript
abundance between patients treated with high-dose
Table 2. Plasma cytokine concentrations 2 days post initiation of treatment.
Cytokine Plasma concentration 2 days after starting therapy Trend test**
High-dose prednisolone Low-dose prednisolone Placebo Multiplicative effect Adjusted P
(Fever day* =22 (24, 22)) (Fever day =22 (24, 22)) (Fever day =23 (24, 22)) (95%CI)
IL-1b 11.3 12.5 13.1 0.90 0.24
(8.5–15.1) (10.7–16.3) (10.2–18.3) (0.75–1.07)
IL-2 50.6 54.6 50.9 0.89 0.31
(37.6–66.6) (40.2–69.5) (38.4–74.6) (0.72–1.11)
IL-4 13.4 14.1 13.3 0.91 0.29
(10.2–17.2) (10.2–16.9) (10.0–19.0) (0.77–1.08)
IL-5 79 79 79.3 0.91 0.42
(62.6–101.1) (63.3–92.0) (64.6–96.4) (0.73–1.14)
IL-6 132.9 125.7 140.1 0.98 0.83
(93.3–183) (106.4–162.4) (102.3–199.6) (0.80–1.20)
IL-10 119.4 118.2 126.7 0.98 0.65
(80.8–166) (96.7–152.6) (98.4–167.4) (0.92–1.05)
IL-12p70 24 23.1 23.2 0.97 0.70
(16.0–32.4) (16.0–30.1) (15.8–30.2) (0.82–1.14)
IL-13 26.4 23.6 25.6 0.94 0.42
(17.3–40.1) (17.1–40.1) (18.5–36.1) (0.80–1.10)
IFN-c 56.5 58.1 62.2 0.97 0.48
(41.0–96.0) (42.4–88.5) (41.8–85.3) (0.87–1.06)
TNFa 13.2 12.7 14.5 0.95 0.56
(10.6–17.6) (10.2–16.2) (10.0–18.1) (0.780–1.13)
IP-10 8398 8097.5 8099 1.06 0.14
(5,099.2–11,506.5) (4,998.9–11,424.4) (4,701.8–10,630.3) (0.98–1.14)
All data are presented as median (IQR) values.
*Fever day (median (IQR) refers to the day of sampling relative to the day of defervescence, defined as fever day 0.
**Trend test using multivariable linear regression of log transformed values adjusted for pre-treatment value and day of illness at enrolment. The effect corresponds to
the estimated multiplicative difference between low-dose vs. placebo or high-dose vs. low-dose, respectively, which were assumed to be identical as a linear dose-
response effect was estimated.
doi:10.1371/journal.pntd.0002592.t002
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prednisolone and placebo. * Trend test using multivariable
linear regression of log transformed values adjusted for pre-
treatment value and day of illness at enrolment. The effect
corresponds to the estimated multiplicative difference between
low-dose vs. placebo or high-dose vs. low-dose, respectively, which
were assumed to be identical as a linear dose-response effect was
estimated. a All p values were corrected with Benjamini-Hochberg
method for multiple test correction. NS denotes genes that were
not significantly different in gene expression between the patients
receiving low dose prednisolone and placebo and/or that the 95%
confidence interval of the relative expression ratio contained 1.
(DOC)
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